This round is no longer accepting investments, but hundreds just like it are live now.



A Better Approach to Breast Imaging

At Koning Health, we designed a breast-only CT scanner for highly accurate early detection of breast cancer without the uncomfortable compression of mammograms. Our highly detailed 3D imaging aims to detect cancer at its earliest stages, preventing the need for tedious recovery processes and potentially saving the lives of millions.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$575,447.14 Raised

Reasons to Invest

  • Lifesaving technology: Our technology detects tumors as small as 2 millimeters and calcifications as small as 200 microns, allowing for the diagnosis of Stage 0 and 1 cancers before they can spread while they still have a 99%+ five-year survival rate. 
  • Regulatory approval: The US market for breast imaging is preparing for rapid expansion, with 6 dedicated CT CPT codes that went into effect in 2021 providing reimbursements to private and public payers (AMA, CMS).
  • Seasoned management team with significant fundraising experience: 
    We have raised $55 million to date through venture funding, and $2.5 million on, demonstrating a proven track record for raising funds. We have signed agreements with several new hospitals and clinics for installations in the upcoming year.


Bringing Breast Imaging into the 21st Century

Koning Health manufactures an FDA-approved diagnostic breast CT device already being used in clinics around the world. Our 3D imaging requires no painful compression and provides highly accurate detection of Stage 0 and 1 cancers, especially in patients with small or dense breasts or implants where mammograms often cannot detect small tumors. 

The Koning Breast CT (KBCT) is the first of its kind to be in-market. We believe we have the potential to save millions of lives as the comfort of our procedure encourages more frequent imaging and the accuracy of our technology detects cancer before it spreads. 

The Problem

Mammograms are Uncomfortable and Provide Limited Detection

There are over 83 million women in the U.S. who are 40 years and older (Source). However, according to the MQSA (Mammography Quality Standards Act Program), only 40 million women were reported to get their annual mammogram last year (Source). This makes for over 50% non-compliance rate in regards to women who receive their annual breast exam.

Breast cancer is the most diagnosed cancer in women in the U.S. and the second leading cause of cancer death in American women. With breast detection Stages 0 or 1, there is a 99% 5-year survival rate. However, with Stage 4 detection, that number drops to 22%.

Mammograms are a lifesaving procedure, however, the limitations of 2D imaging cause mammograms to fail to detect up to 30% of early stage breast cancers, a number that rises to 70% for women with dense breasts. 

The Solution

Improved Breast Imaging for Better Diagnostics

*The above is a rendering of the company's product. Images are computer generates demo versions. Product is currently in use globally. g

The KBCT delivers high contrast 3D breast imaging without the need for painful compression. In a rapid 7-second exposure with the patient in a comfortable prone position, the KBCT takes a 360-degree scan, allowing for the evaluation of breast tissue from all angles. Our technology is able to detect Stage 0 and 1 tumors as small as 2 millimeters and calcifications as small as 2 microns, making early detection easier than ever. 

Dr. Richard Ha, a prominent Breast MRI specialist familiar with Breast CT has stated: Mammography detects on average 3 to 4 breast cancers per thousand while DBT is said to detect 4 to 5 per thousand. Multiple publications have shown Breast MRI sensitivity and specificity increases the detection rate up to 20 to 24 per thousand. Dr. Ha predicts Breast CT with contrast will be on par with Breast MRI detection rates. Breast CT introduces compression free, low dose and true 3-dimensional breast imaging and unlike Breast MRI, Breast CT can visualize calcifications, often an early indicator of disease (Dr. Richard Ha - Columbia University Irving Medical Center).

Currently, we sell our devices to clinics and hospitals around the world, and we also provide a fee-for-scan option to clinics that cannot afford the whole price upfront. As we grow, we plan to build our own “Koning Clinics” managed by partner doctors so our technology can be made available to patients on as great a scale as possible. 

The Market

Koning Accelerates Commercialization with New Go-to-Market Plan

Koning is ushering in a new business model that caters to retail healthcare with Koning Clinics in major metropolitan areas. Once the pilot program is complete, we plan to expand through the use of retail partners like CVS, Walgreens, etc.

The US market for breast imaging is preparing for rapid expansion, with 6 dedicated CT CPT codes approved as of May 2020 providing reimbursements to private and public payers. These dedicated breast CT CPT codes demonstrate a growing demand in the industry for breast CT. 

Our Traction

Enthusiastic Support for Our Patented, Approved Technology

Since our launch, we have hit a number of major milestones: 

  • 120 patents, with 6 additional patents filed and pending. 
  • FDA and EMA approval for the device. 
  • Regulatory approval in North America,  Australia, and across countries in Asia. 
  • 20 installations around the world, illustrating rapid growth.
  • Over 25,000 patients scanned using our technology. 
  • Previous crowdfunding raise on of $2.5 million. 
  • Version 2 of the Koning Breast CT, rebranded as Vera by Koning. 
  • Signed agreements with several new hospitals and clinics in the US with installations upcoming this year, starting with Arkansas Heart Hospital in Little Rock, AR. 


Collaborating to Expand Access to 
Our Technology

Remote Readers

As Koning grows and expands not only into more hospitals, but also into family clinics around the country, we will be partnering with DocPanel, the world’s first on-demand, pay-as-you-go, contract-free service offering radiological reads, second opinions, educational consults, and diagnoses from high-caliber subspecialty radiologists at prestigious academic hospitals. This partnership is key to Koning’s expansion and will alleviate any issues that might have arisen.


Koning is partnering with Alpha Medical Equipment Company, an exclusive distributor and service provider of medical diagnostic imaging equipment throughout the New York, New Jersey, and Northeastern Pennsylvania areas.

Why Invest

Building a Better Future for Breast Cancer Treatment


Koning is the only independent and dedicated breast CT company, with compelling advantages over existing modalities. Our competition is focused on making 

incremental improvements in CT, MRI, X-ray tomosynthesis and ultrasound, whereas we use novel technology to get a clearer picture of each patient. Given the historical precedent set by DBT, we believe that KBCT will soon dominate the medical landscape for breast imaging.

Koning Breast CT is raising the standards for breast cancer diagnosis and treatment across the globe. Our mission is to save millions of lives through early detection and increased compliance due with our painless imaging. 

In an industry experiencing rapid expansion, we have a product that dramatically improves imaging and diagnostic capabilities protected by 120 patents and already 

in-market. Join us as we provide our lifesaving technology to patients everywhere. 

Bold (⌘B)


5555 Oakbrook Parkway
Norcross, GA 30093

At Koning Health, we designed a breast-only CT scanner for highly accurate early detection of breast cancer without the uncomfortable compression of mammograms. Our highly detailed 3D imaging aims to detect cancer at its earliest stages, preventing the need for tedious recovery processes and potentially saving the lives of millions.


Lutao Ning

Lutao Ning

Chief Executive Officer & Director

Lutao Ning holds an MBA from INSEAD and graduated magna cum laude from Duke University with a BSE in Biomedical Engineering and a Markets and Management Certificate. As a core member of the technology, media and telecom practice area of Boston Consulting Group, he has led case teams for major technology, medical device, and pharmaceutical clients in topics ranging from product development, organizational design, and corporate development. In 2013, he led the effort for the Board of Directors of Dell in the, then, largest take-private transaction in history.

Lutao has worked as an advisor to Koning in business strategies since its inception. His contributions formed the basis of the operations plan and financial forecast. He is now the CEO of Koning US and COO of Koning Global, where he is in charge of business operations, financing, human resources, government relations and regulatory approval.

Ruola Ning

Ruola Ning

Founder and Global Chairman of the Board

Dr. Ruola Ning is a graduate of the University of Utah with an MS and Ph.D. in Electrical Engineering. He is a Professor of Imaging Sciences, and Electrical & Computer Engineering at the University of Rochester, and the inventor of over 80 issued patents for medical imaging technology. He has published and presented over 120 scientific papers at conferences and in peer reviewed journals and has accumulated over twenty years of experience in Cone Beam CT and has been awarded over $11 million in research grants from the National Institutes of Health at University of Rochester.

As a true visionary in his field, Dr. Ning has positioned Koning Corporation to become the commercial leader in Cone Beam CT Technology while continuing to lead his world renowned scientific team in Cone Beam CT research. Dr. Ning was the recipient of the Inventor of Year 2015 grant prize by The Rochester Intellectual Property Law Association (RIPLA). He holds an American Board of Radiology (ABR) Certificate in Diagnostic Radiologic Physics.

Matthew Stack

Matthew Stack

Chief Financial Officer

Matthew Stack is the Chief Financial Officer at Koning Corporation. Matt’s prior experiences include managing acquisitions for a $120M corporate-led technology buyout fund in Palo Alto, as well as spending six years at The Boston Consulting Group in the Boston and New York offices, where he worked on projects in the Health Care, IT, Retail, Industrial Goods, and Strategy practice areas. Before BCG, Matt co-founded and invested in a healthcare software startup, a small electronics company, an advanced composites design firm, and a semiconductor distribution company that traded high performance semiconductor chips between Shenzhen, Tokyo, and Tecate. Matt has also served as the Director of Computational Science at Mars Corporation.

Matt holds a B.S.E. in electrical engineering from Princeton University. He is a benefactor and sponsor of the TEDx conference series, and has sponsored research at the Santa Fe Institute in New Mexico, the Strategy Institute in New York, MIT’s Broad Institute, the Highlands Forum, the University of Oxford, and the Department of Defense.

David Georges

David Georges

US President

David Georges has been a global business leader in Breast Imaging for the past twenty-five years, contributing to the introduction and substantial market growth of innovative products dedicated to the early detection of breast cancer including mammography, breast biopsy, computer aided detection, breast ultrasound and automated breast ultrasound. David has established manufacturing sites, supported luminary sites for new product introduction, and established physician and technologist training centers. He has held senior executive positions in companies such as Transworld, Lorad, Hologic, R2, SuperSonic Imagine, iVu and U-systems; the latter of which was purchased by GE.

Since joining Koning, David has led the effort to move the company from a Research and Development group to one that is prepared for commercializing Koning’s KBCT. David’s industry relationships have introduced opportunities to establish critically important luminary partners. With a knowledge of global distribution, David has expanded the Koning installation base to Thailand, Qatar, and Netherlands.

Naomi Cosman

Naomi Cosman

VP of Marketing

Naomi Cosman is the Vice President of Marketing for Koning and was brought onto the Koning team to implement and direct a clear marketing strategy. She oversees all marketing initiatives including PR, social, creative, website, campaign creation and implementation, and more. 

After graduating from the University of Wisconsin-Madison early with a double major (Communications and French), Naomi received a Certificate of Integrated Marketing from NYU and a Certificate of Business from Harvard Business School. Naomi spent five years in a Fortune 500 company focusing on branding, brand alignment across teams, and campaign launches. She spent another five years working with various startups across multiple sectors, which ultimately led her to Koning Health. 

Naomi works with the rest of Koning’s leadership to build on previous marketing work. She brings a unique perspective to the company with the goal of increasing Koning’s overall brand awareness, public outreach and communications - all in a way worthy of a revolutionary women’s healthcare company. 

Ty Cowart

Ty Cowart

Senior Director of Global Regulatory Affairs and QA

Mr. Cowart brings over 35 years of experience bringing novel medical technologies to market through the regulatory process of FDA, BSI, TUV, TGA, EU, as well as CFDA and Japan ministry of health. Mr. Cowart has led 15 successful PMA processes, and dozens of PMA supplements, 510 Ks and related approvals. Most recently, Mr. Cowart was the Senior Director of Regulatory of Cardio Mems, a class III invasive surgical implant, achieving a PMA approval in record time. Mr. Cowart will be responsible for ensuring QA compliance is followed and the regulatory approvals and supplements for the KBCT systems are achieved in the most expedient and efficient manner. Mr. Cowart is a graduate of the University of Georgia with MPA and MBAs from Georgia Southern and a JD from Woodrow Wilson College of Law.
Shawn Liu

Shawn Liu

Director of R&D

Mr. Liu earned his MS degree in Software Engineering from Tsinghua University and MS degree in Electrical & Computer Engineering from University of Rochester. He has nearly 20 years’ experience of software and hardware design, development and management, including distributed information systems, compute-intensive applications and real-time control systems. He also has nearly 15 years of extensive experience in medical system development, image analysis and processing, accurate 3D reconstruction and rendering, and computer-aided detection/diagnosis based on big data and deep learning. He has participated in a number of government grants related to cone beam CT research worldwide, and holds several patents. He joined the Cone Beam CT research lab at University of Rochester Medical Center in 2005 and has been involved in cone beam CT system integration and image research. 

He joined Koning in 2008 and has been spearheading the work for the system design and control, image acquisition and processing, system integration and other R&D works of Koning Breast CT and its successors. He also participated in the leadership of the quality management, clinical trials and regulatory approvals in various regions over the world. He has a wealth of knowledge and experience for product development and team leadership

Dr. Roger Zhang

Dr. Roger Zhang

Director of Clinical Affairs

Dr. Roger (Xiaohua) Zhang graduated from University of Rochester with a PhD of Electric and Computer Engineering. Dr. Zhang has more than 15 years of experience in Koning Breast CT technology and breast imaging modalities. 

As the Imaging Scientist and Director of Clinical Affairs of Koning Corporation, Dr. Zhang took part in the design and evaluation of Koning’s products and hardware/software features. Throughout his time at Koning, Dr. Zhang has led many projects on Koning Breast CT clinical evaluation and has worked closely with clinical experts in clinical studies to evaluate the safety and efficacy of Koning products in a clinical application environment.

Kathy Byrnes

Kathy Byrnes

Clinical Specialist

Clinical applications specialist for an elite group of 16 individuals in a start-up, first-of-its-kind medical imaging device company. Supervise and manage first US install of unit, integration of imaging software and training radiologists and techs in utilization and applications of Breast CT scanner. Currently registered and licensed as radiologic technologist. Extensive knowledge of medical procedures and protocols in hospitals as well as clinical settings.
Dr. Rajesh Garg

Dr. Rajesh Garg


Dr. Garg is a strategic, inspirational, values-based health care leader with a proven P&L track record. He is deeply experienced across multiple segments of health care including biopharma, providers/payors, medical device, and ancillary service companies. He builds exceptional aligned senior teams with commitment to delivering tangible results. His global experience spans North America, Europe and Asia and substantive expertise covers the corporate value chain as well as a broad range of C-suite topics. 
Dr. Changhua Qiu

Dr. Changhua Qiu


Experienced Professional with a demonstrated history of substantial value-add for clients in the financial services industry. Skilled in Investment Management, Equity Research, Start-ups, Corporate Finance, and Scientific Research. Strong education background with a MBA focused in Finance and a Ph.D in Applied Physics. 
Dr. Baozhong Wang

Dr. Baozhong Wang


Mr. Baozhong Wang is currently the Chairman of Beijing Dingxin Lianrui Investment Co., Ltd. Mr. Wang Baozhong has served as the director of Zhonghengxin CPA Accounting Firm, the deputy general manager of China Beijing International Economic Cooperation Corporation, the chairman of Beijing Guoyuan Investment Consulting Co., Ltd., and the independent director of Zhongguancun Science and Technology Development Co., Ltd. (a listed company). With a deep professional background in accounting, finance, business administration, etc., he has held leadership positions in various types of enterprises, presided over and implemented a number of investments, mergers and acquisitions and restructuring projects. He has a deep understanding of enterprises, and has rich practical experience in investment management, enterprise restructuring, listing, and mergers and acquisitions. Mr. Wang holds a Master of Accountancy from Northeastern University in Finance and Economics, a Ph.D. in Finance from Renmin University, and an MBA from Roosevelt University (USA). In addition, Mr. Wang Baozhong is a certified public accountant and certified asset appraiser.
Lianghai Bing

Lianghai Bing


Mr. Hai Bing Liang, Chinese citizen, is appointed as Executive Director at China Venture Capital Association, Vice Director at Shanxi Venture Capital Association, and Vice President at Shanxi Credit Association. He is a legally qualified lawyer, and has obtained Bachelor of Law from Northwest University of Politics and Law, Master of Economics from Xi’an Jiao Tong University, EMBA from Cheung Kong Graduate School of Business, and Doctor of Business Administration from Xi’an Jiao Tong University. 

He has 17 years of work experience in financial investment and organizational management. With his rich experiences in the field of scientific and technological innovation and venture capital investment, he has provided investment and management services for hundreds of institutions.

Lee Fan

Lee Fan


Lee Fan is a cross functional tech executive with over sixteen years of finance and venture capital experience on Wall Street and in Silicon Valley. She brings a unique blend of financial expertise, strategic advisory, and operational skills to tech, crypto, and investing. Lee holds a B.S. degree in Economics from Duke University (2006) with minors in Biology and Japanese, and an MBA from Wharton at the University of Pennsylvania (2011). From 2006 to 2017, Lee had a decade long career in investment banking at Morgan Stanley, Evercore Partners, and Bank of America Merrill Lynch, advising her clients on strategic capital market and M&A opportunities. She has worked on dozens of IPOs, Follow-On Offerings, and M&As across healthcare, consumer retail, and internet industries. After her successful career in investment banking, Lee served as Senior Vice President at ZZ Ventures, where she led the investing effort in disruptive technology companies with a primary focus on consumer internet and fintech startups. Lee was the first Chief Financial Officer at GrubMarket from 2018 to 2020. She also works with the SPAC sponsor Trepont Acquisition Corp. Lee is currently the Chief Strategy Officer of BitMart, a top tier digital assets trading platform and exchange. Additionally, Lee serves on Board of Directors and Advisory Board for tech startups and VC funds.  


Dec. 31, 2022 at 7:59 AM UTC
$10k - $2.9M
Common Stock
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*


Platinum Early Bird

Invest within the first 24 hours and receive 15% bonus shares.

Gold Early Bird

Invest within the first week and receive 10% bonus shares

Silver Early Bird

Invest within the first two weeks and receive 5% bonus shares

Amount Based:


Mention on website, newsletter access


Free exam at Koning Headquarter Clinic.


2 free exams + Zoom call with founders

Previous Backer Bonus

All previous investors will receive an additional 5% bonus shares when they invest in this raise. 

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Metric Medical will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $5.69 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $569. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the Previous Backer Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company will not incur any irregular use of proceeds.


Article Image
PR Newswire

Koning Ends the Year with $2.6M Republic Raise

Article Image
PR Newswire

Koning Begins FDA Clinical Screening Trial in Daytona Beach, Florida

Article Image
PR Newswire

Koning Announces Partnership to Get Ten Breast CT Devices Installed in Southeast Asia in Time For Breast Cancer Awareness Month



Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Koning.


Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

Owners bonus

Owner’s Bonus

Owner’s Bonus Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).



Michael Celaya

2 months ago

Hello Lutao, I invested in a previous round. Do you know how soon Koning plans to start building and installing the smaller/lower cost units in the Pharmacy stores/chains? What are your thoughts on the possibility of Koning growing faster by starting the build & installation plan of the smaller/lower cost units starting in 2024?



Richard Koch

a year ago

It's good to see that your units are made in the USA. I'm curious, how much exposure do you have to foreign sources of supply? Is your supply chain sound?



Michael Nadler

a year ago

Is the goal to be acquired or go the IPO route in the future?



Arturo Munguia

a year ago

How many patients have been reached as of now? Are things moving at a faster pace now? Is the slowdown still due to parts or chips for the machine? How many more machines do you plan to have out there by end of quarter 1 2023? Or Total? Thank you.



Jason Kaunas

a year ago

In 2021, the global mammogram market is estimated at 2B, with $659M in the U.S. Most estimates have the global breast imaging market to be around 4B or 5B in 2021. In your past responses you have indicated that you believe the TAM for Konig is approximately $40B. Given the market data and your desire to compete with/replace/disrupt the current mammogram/breast imaging market, how are you coming up with the $40B figure for TAM?




a year ago

How many machines have you sold to date. How much does a machine and installation cost. Would it require a forklift to install. If a hospital orders one today. How long does it take for it to get the machine. Where are they made? Any supply chain problems? How much does one machine cost? When do you expect your company to be profitable? When do you expect to go public? Will you need to raise more money after this raise?



Vicki Vitkun

a year ago

Will Medicare or traditional health insurance require a questionable standard mammogram diagnosis prior to paying for the KBCT exam? Your recent partnerships with 11Ten and DocPanel are amazing!! We will invest in this round.



Francis Erdman

a year ago

What is the total addressable market for this type of medical scanning technology over say the next 10 years and what percentage of that TAM do you think you can get over 10 years? (Maybe how big is medical scanning technology market in general, and breast scanning technology in particular? If say you target to get say 50% of the breast scanning market, or whatever your target is, would you then branch out into other types of medical scanning technology (say, brain scans)?) Just trying to get idea of potential future growth here, thanks.



Larry Gardner

a year ago

I invested with y’all when you with republics investment can you tell me what happened with my investment when y’all moved to start engine please



Larry Gardner

a year ago

I invested with y’all when you with republics investment can you tell me what happened with my investment when y’all moved to start engine please




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!


With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


Get To Know Us

Our Team



Important Message

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA / SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from (the any security. It also does not constitute an offer to provide investment advice or service. any security. It also does not constitute an offer to provide investment advice or service. any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.